The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform. The company said Tuesday it now provides access to Zepbound, a brand-name version of the drug tirzepatide,

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss platform.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's direct-to-consumer online healthcare platform, LillyDirect.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The restrictions began because the FDA declared a shortage of tirzepatide, often sold as Zepbound, and semaglutide, often sold as Wegovy, over.

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay later under a partnership

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a few setbacks in recent months, its stock has strengthened. The up-and-coming telehealth player offers a direct-to-consumer platform providing access to a wide range of health and wellness products and services.

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.